Dihexa: The Angiotensin IV Analogue and Its Very Preclinical Evidence

Dihexa has one of the more precisely characterised mechanisms among compounds sold as research peptides, and essentially no human evidence. Those two facts are both worth stating plainly, because the first is often used to imply the second.

What it is

Dihexa is a small angiotensin IV analogue developed in academic research into cognitive decline. Angiotensin IV is a fragment of the renin-angiotensin system with activity in the brain distinct from the blood pressure roles the system is known for.

A 2014 paper in the Journal of Pharmacology and Experimental Therapeutics found that the procognitive and synaptogenic effects of angiotensin IV-derived peptides depend on activation of the hepatocyte growth factor / c-Met system. A 2015 Progress in Neurobiology review covers the broader development of small-molecule angiotensin IV analogues for Alzheimer’s and Parkinson’s disease.

Where the evidence stops

Every published finding is preclinical. The compound was developed in an academic programme aimed at neurodegenerative disease, and it did not progress to human trials. Nothing about a compelling rodent mechanism guarantees it would have.

The c-Met question

The same mechanism that makes dihexa interesting is the one that warrants the most caution, and it is rarely raised.

This is not a claim that dihexa causes cancer — no data exists either way. It is the observation that the mechanism cuts in a direction worth taking seriously, and that the absence of human data means the question is open rather than answered.

How it compares in this category

Dihexa sits at the far preclinical end of a category that already skews preclinical. Semax and selank at least have human trial literature, however hard to appraise. See semax vs selank and the peptides for anxiety guide.

Is it even a peptide?

Dihexa is usually described as a peptide and is more accurately a modified tripeptide derivative — engineered specifically to be more lipophilic and metabolically stable than the parent angiotensin IV fragment, so that it could cross the blood-brain barrier.

That modification is the point of the molecule. It also means it does not behave like a typical peptide, and comparisons to peptide dosing conventions do not transfer. The peptide vs protein guide covers where these boundaries sit.

What would change the picture

1. A phase 1 human safety study, which does not exist.

2. Human pharmacokinetics — dose, exposure, half-life.

3. Any carcinogenicity assessment, given the c-Met mechanism.

4. An independent replication of the synaptogenesis findings.

5. A cognitive endpoint measured in people rather than inferred from rodents.

Until then, "studied for cognition" means studied in animals, and the list of peptides guide places it in the preclinical tier for that reason.